Profile data is unavailable for this security.
About the company
Vaishali Pharma Limited is an India-based pharmaceutical company. The Company is in the pharmaceutical business, mainly dealing in active pharmaceutical ingredients, pharmaceutical formulations, surgical products, and veterinary supplements, operating in domestic and export markets. Its product categories include active pharmaceutical ingredients (APIs), formulation brands, formulations, herbal, nutraceutical, oncology, surgical, and veterinary. The Company has manufactured and exported approximately 250 formulations and specializes in manufacturing tailor-made formulations. It offers APIs, including antibiotics, anti-ulcer, anti-inflammatory/analgesic/ anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, antiviral, antifungal, skeletal muscle relaxant, and anthelmintic drugs, excipients, topical steroids, corticosteroids, and enzymes. It has a global presence in Asia & Pacific, Africa, the Commonwealth of Independent States, America, and the Middle East.
- Revenue in INR (TTM)1.17bn
- Net income in INR-3.86m
- Incorporated2008
- Employees--
- LocationVaishali Pharma Ltd706-709, Aravalli Business Center R.C.Patel Road, Sodawala Lane, Borivili (West)MUMBAI 400092IndiaIND
- Phone+91 2 242171819
- Fax+91 2 228928833
- Websitehttps://www.vaishalipharma.com/
Mergers & acquisitions
| Acquired company | VAISHALI:NSI since announced | Transaction value |
|---|---|---|
| Kesar Pharma P Ltd | -46.75% | 2.35m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accretion Pharmaceuticals Ltd | 573.76m | 67.94m | 761.45m | 121.00 | 11.21 | 4.98 | 10.06 | 1.33 | 6.11 | 6.11 | 51.62 | 13.75 | -- | -- | -- | 4,741,835.00 | -- | -- | -- | -- | 30.44 | -- | 11.84 | -- | 0.557 | 8.30 | 0.4799 | -- | 70.43 | -- | 75.30 | -- | -- | -- |
| Zenith Drugs Ltd | 1.44bn | 37.77m | 793.99m | 182.00 | 21.03 | 1.11 | 8.76 | 0.552 | 2.20 | 2.20 | 83.88 | 41.82 | 0.9315 | 2.80 | 2.33 | 7,903,775.00 | 2.45 | -- | 4.48 | -- | 33.80 | -- | 2.63 | -- | 0.9561 | 1.54 | 0.4198 | -- | 1.29 | -- | -24.92 | -- | -- | -- |
| Curis Lifesciences Ltd | 502.59m | 62.06m | 840.78m | -- | 13.55 | 5.09 | 12.22 | 1.67 | 7.68 | 7.68 | 62.17 | 20.43 | -- | -- | -- | -- | -- | -- | -- | -- | 36.59 | -- | 12.35 | -- | 0.7449 | 27.07 | 0.486 | -- | 41.27 | -- | 23.51 | -- | -- | -- |
| Vaishali Pharma Ltd | 1.17bn | -3.86m | 852.18m | -- | 24.40 | 1.54 | 492.87 | 0.7262 | 0.3258 | 0.3258 | 11.82 | 5.16 | 1.04 | 54.91 | 2.48 | -- | -0.3418 | 3.19 | -0.5293 | 6.67 | 11.29 | 15.64 | -0.3289 | 3.43 | 2.33 | -1.59 | 0.188 | -- | 14.77 | 10.51 | 13.70 | 90.26 | 42.08 | -- |
